BioXcel Therapeutics

CompanyUnited StatesFounded 2017

BioXcel Therapeutics develops one asset, in phase 3 (BXCL501 in agitation). Mostly small molecule acting on ADRA2A; based in the United States, founded in 2017.

1
Asset
Furthest: Phase 3; 1
Trial: 0
Signals

Pipeline

1

BXCL501
Selective alpha-2 adrenergic receptor agonist
Phase 3, Small molecule, ADRA2A, agitation, dementia

Full company profiles: pipeline, trials, funding and people.

In the full profile

Trials1
Similar companies6

Updated 8 Oct 2026 · 5 sources